Neos Therapeutics Inc. (NEOS) said that it has entered into a confidential settlement and licensing agreement with Teva Pharmaceuticals USA Inc. to resolve all ongoing litigation involving Neos' patents protecting its Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets and Teva's Abbreviated New Drug Application or ANDA filed with the U.S. Food and Drug Administration to market a generic version of that product.
Neos is a pharmaceutical company focused on developing, manufacturing, and commercializing extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms.
As per the settlement and license agreement, Neos has granted Teva the right to manufacture and market its generic version of Cotempla XR-ODT under the Teva ANDA beginning on July 1, 2026, or earlier under certain circumstances.
The settlement and licensing agreement is confidential and the agreement is subject to submission to the Federal Trade Commission and the U.S. Department of Justice.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.